Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC1 Cell Therapy for Post-Traumatic Syringomyelia
NCT02807142Phase 2Completed
- Sponsor
- Hospital Universitario Puerta de Hierro Majadahonda
- Start
- Mar 2016
- Primary completion
- Feb 2018
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow stromal cells in Post-traumatic syringomyelia (PTS), sponsored by Hospital Universitario Puerta de Hierro Majadahonda. Primary endpoint: American Spinal Injury Association Impairment Scale at Month 6. Started Mar 2016; status: completed.
02
Drugs
autologous bone marrow stromal cells
03
Conditions
Post-traumatic syringomyelia (PTS)
Beyond the preview
Go deeper on NCT02807142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807142.